Brizantin

General characteristics. Structure:

Active agents: antibodies to mozgospetsifichesky protein S-100 affinely cleared – 0.006 g *
Antibodies to a kannabinoidny receptor of the I type affinely cleared – 0.006 g *
Excipients: lactoses monohydrate, cellulose microcrystallic, magnesium stearate.
 
* are applied on lactose in the form of mix of three active aqueous-alcoholic cultivations of the substance divorced respectively in 10012, 10030, 100200 times.

Pharmacological properties:

Pharmacodynamics. The combined drug:
Antibodies to mozgospetsifichesky protein S-100 render antioxidant, antigipoksantny, neurotyre-tread, anxiolytic, antidepressive action. Modify functional activity of the protein S-100 which is carrying out interface of information and metabolic processes in a brain. Possess membranotropny action, causing decrease in amplitude and suppression of generation of action potential; modulate synoptic transfer in limbic structures of a brain, a hippocampus, a reticular formation; promote strengthening of brake influences of GAMK in TsNS. Show properties of an agonist sigma of 1 receptor of in vitro.
Inhibit processes of peroxide oxidation of lipids.
Antibodies to a kannabinoidny receptor of the I type modulate functional activity of a kannabinoidny receptor of 1 type, influence concentration of intracellular tsAMF. Regulate endokannabinoidny system in TsNS (mainly in neurons of mesolimbic system) and peripheral fabrics, normalize power balance (metabolism of glucose and lipids).
Experimentally, on models of self-stimulation of a lateral hypothalamus the synergy antiaddiktivny effect when sharing both components as a part of complex drug is shown Brizantin.
Brizantin modulates system of a positive emotional reinforcement, reducing thereby expressiveness of an inclination to psychoactive agents at alcoholism and a nicotinism; normalizes balance of neurotransmitters of TsNS.
Brizantin also shows neurotyre-tread activity, increases resistance of a brain to toxic influences, improves integrative activity, promotes elimination of cognitive disturbances, increases intellectual working capacity, normalizes somatovegetativny manifestations at abstinent states.
Drug eliminates affective (irritability, decrease in mood, internal discomfort), ideatorny (thoughts of nicotine or alcohol) and astenovegetativny disturbances (the expressed general weakness, decrease in working capacity, appetite, perspiration, tachycardia, etc.). Has no sedative, miorelaksantny effect; does not cause accustoming, medicinal dependence; has no narcogene potential.

Pharmacokinetics. Sensitivity of modern physical and chemical methods of the analysis (gas-liquid chromatography, highly effective liquid chromatography, chromaTO - mass spectrometry) does not allow to estimate the maintenance of midget doses of antibodies in biological liquids, bodies and fabrics that makes technically impossible studying of pharmacokinetics of drug Brizantin.

Indications to use:

Drug is used for reduction of an inclination to alcohol and nicotine as in the first days of refusal of their reception (the abstinence period), and at impulsively shown desire of their use.

Route of administration and doses:

Inside. On one reception - 1 tablet (to hold in a mouth before full dissolution). To apply on 1 tablet 2-3 times a day out of meal. When strengthening an inclination to alcohol and/or nicotine increase in frequency of reception up to 5-6 times a day is possible.

Features of use:

Lactose in this connection patients are not recommended to appoint it with an inborn galactosemia, a sprue of glucose or a galactose, or at an inborn lactose intolerance is a part of drug.
Brizantin does not exert impact on ability of control of vehicles and other potentially dangerous mechanisms.

Side effects:

Reactions of the increased individual sensitivity to drug components are possible.

Interaction with other medicines:

Cases of incompatibility with other medicines are not registered so far.

Contraindications:

The increased individual sensitivity to drug components. Brizantin is not recommended for use for children aged up to 18 years in connection with insufficiency of data on efficiency and safety for this age.

Pregnancy and period of a lactation
Safety of use of Brizantin at pregnancy and in the period of a lactation was not studied. In need of administration of drug it is necessary to consider a ratio risk/advantage.

Overdose:

At accidental overdose the dispepsichesky phenomena caused by the fillers which are a part of drug are possible.

Storage conditions:

In the place protected from light, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

Tablets for a rassasyvaniye. On 20 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil.
On 1, 2 or 5 blister strip packagings together with the instruction on a medical use place in a pack from a cardboard.